Tevogen

A Healthcare Company

[Tevogen Bio @TevogenBio]

A little #TBT to a day we will never forget.
We are proud of how far we have come, and even more energized by where we are headed.
$TVGN @Nasdaq @TevogenAI @Tevogen

[Ryan Saadi, Founder, TEVOGEN @DrRyanSaadi]

The most powerful pharmacy in the world isn’t on a street corner. It’s already inside our veins. @TevogenBio - #Tcell
🌐 https://t.co/9FOwy8XEKJ $TVGN

[Tevogen Bio @TevogenBio]

📰 https://t.co/0Rj0z1Tq5A

“Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to building revenue-generating capabilities that may support long-term financial self-sufficiency,” said Kirti Desai, Chief Financial Officer at Tevogen. “With approximately $100 million in potential combined annual revenue under evaluation, we believe these opportunities could represent an important step toward strengthening the Company’s financial foundation while remaining aligned with our mission to make healthcare more affordable and accessible.”

$TVGN #HealthcareEnterprise #StrategicAcquisitions #Revenue @DrRyanSaadi

[Tevogen Bio @TevogenBio]

At JPM43 Mittul Mehta, @Head_TevogenAI and @drhew
Chief Medical Officer & VP of Healthcare at
@Microsoft discussed AI in Biopharma: Next Frontier of Medical Innovation

$TVGN $MSFT @DrRyanSaadi #Healthcare #ArtificialIntelligence #AI #Innovation #ICYMI

[Tevogen @Tevogen]

RT @TevogenBio: Dr. Neal Flomenberg, Chief Scientific Officer, and Lori Grosso, Clinical Lead, discussed @TevogenBio's goal of making cytot…

[Tevogen @Tevogen]

RT @TevogenBio: 📰 https://t.co/A0DpFyP70F

“Capital discipline and preserving the integrity of our capital structure are core priorities fo…

[Tevogen Bio @TevogenBio]

📰 https://t.co/GGtieRNxdZ

“We anticipate this opportunity together with previously announced CRO evaluation and other strategic acquisition initiatives, if consummated, could potentially pave Tevogen’s path to realizing approximately $100 million in combined annual revenue,” said Tevogen founding CEO @DrRyanSaadi

$TVGN #StrategicAcquisitions #RevenueGeneration #HealthcareEnterprise

[Tevogen Bio @TevogenBio]

📰 https://t.co/BHcnJowd5K

🔹Loss from operations declined 51%, from $53.6 million in 2024 to $26.1 million in 2025.

🔹Q1 2026 showed continued improvement, with loss from operations decreasing to $5.4 million, a 48% improvement year-over-year.

🔹The Company is evaluating potential revenue-generating acquisitions that may support positive cash flow and business diversification.

🔹The Company continues to prioritize disciplined capital allocation and avoiding unnecessary dilution.

More in the link.
Thank you for your continued trust and support.

$TVGN #ShareholderValue #CapitalDiscipline

[Tevogen Bio @TevogenBio]

📰 https://t.co/MJvMGLLyoU

“Having The Patel Family, LLP continue to support Tevogen reflects a shared belief in both our mission and our long-term vision for building a more accessible and sustainable healthcare model,” said Tevogen founding CEO @DrRyanSaadi. “We believe this financing along with an existing ATM offering and loan agreement, provides the company with access to adequate capital to reach revenue milestones.

$TVGN #PIPE #RevenueGrowth #HealthcareInnovation

[Tevogen Bio @TevogenBio]

📰 https://t.co/tMwk9ax3lO

“Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said @Head_TevogenAI Mittul Mehta, “As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.”

$TVGN #PredicTcell #ArtificialIntelligence #MachineLearning #DrugDiscovery #Immunotherapy

[Tevogen Bio @TevogenBio]

🔗 https://t.co/CvvZCoRGzs

As part of our ongoing work on PredicTcell™, we’ve been leveraging scalable data infrastructure to process and analyze hundreds of millions of peptide sequences across diverse disease areas.

This recent feature by @databricks highlights elements of that journey, how modern data architecture can support complex biological modeling and help move from static datasets toward adaptive, continuously learning systems.

Thank you, Databricks, for supporting @TevogenAI’s journey toward what we consider the “holy grail”: 𝘵𝘩𝘦 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 𝘵𝘩𝘦 𝘱𝘳𝘰𝘵𝘦𝘰𝘮𝘦 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘨𝘪𝘷𝘦𝘯 𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘢𝘯𝘥 𝘏𝘓𝘈 𝘵𝘺𝘱𝘦.

$TVGN #ArtificialIntelligence #MachineLearning #Bioinformatics #DataEngineering #AIinHealthcare

[Tevogen Bio @TevogenBio]

📰 https://t.co/FwYDYfvrHc

With compliance restored, Tevogen continues to advance its evolution into a diversified, fully integrated healthcare enterprise, combining immunotherapy, artificial intelligence, and disciplined capital allocation to drive long-term value.

The Company’s strategic direction includes evaluating targeted acquisition opportunities that complement its core platforms. These initiatives are part of a broader effort to transition toward a cash-flow-positive operating model while maintaining a strong commitment to affordability and efficiency.

$TVGN #Nasdaq

[Tevogen Bio @TevogenBio]

📰 https://t.co/6zUI9q74SM

@DrRyanSaadi, Founder and CEO of Tevogen stated, "Long COVID is a clinical emergency affecting hundreds of millions of people globally. Our proof-of-concept data demonstrated that none of the patients treated with TVGN 489 for acute infection developed Long COVID. Our expanded HLA coverage now reaching 65% of the U.S. population, and potential digital health acquisitions move us toward building the infrastructure needed to launch our next clinical phase with precision and scale."

$TVGN #LongCOVID #TCellTherapy #PublicHealth #LongCOVIDAwareness #LongCOVIDAwarenessMonth

[Tevogen @Tevogen]

RT @TevogenBio: 📰 https://t.co/1Q83ya3Zkr

“The potential acquisition of a CRO could introduce revenue-generating service capabilities whil…

[Tevogen @Tevogen]

@TevogenBio @TevogenAI @DrRyanSaadi The potential transaction is being explored to augment Tevogen’s existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise.

$TVGN #Sciometrix #Clinicus #HealthcareTechnology #Revenue #Strategy

[Tevogen @Tevogen]

📰 https://t.co/NbkjzEnqZU

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

$TVGN #Sciometrix #Clinicus #HealthcareTechnology #Revenue #Strategy @TevogenBio @TevogenAI

[Tevogen Bio @TevogenBio]

👏On February 15, Tevogen marked two years as a publicly traded company on @NasdaqExchange .👏

Over the past year, we strengthened our proprietary ExacTcell™ platform, broadened our cytotoxic T lymphocyte (CTL) pipeline across viral and oncology indications, and progressed toward establishing in-house GMP cell therapy manufacturing capabilities.

In parallel, @TevogenAI continued its rapid evolution, working toward enabling future clinical trial optimization through proprietary analytics and patient-matching technologies, while expanding collaboration with @databricks and @Microsoft to support development of the beta version of its target discovery platform, PredicTcell™, with a focus on oncology.

Tevogen was built to be different. Disciplined, scalable, and execution-driven.

To our shareholders, partners, and team, thank you for believing in the mission.

$TVGN #ShareholderValue #CapitalDiscipline #HealthcareAI

[Tevogen @Tevogen]

📰 https://t.co/KODvNa7w61

Tevogen announced its Board will evaluate a potential one-time special cash dividend, contingent on future revenue and earnings milestones and Board approval.

$TVGN @Nasdaq #ShareholderValue #CapitalDiscipline

[Tevogen Bio @TevogenBio]

📰 https://t.co/XA3uCuHRbm

“Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company’s goal is to launch at least four blockbuster products by 2030, and to pursue revenue generation in 2026 through our current programs, potential asset acquisitions, and joint ventures.” - @DrRyanSaadi

$TVGN #CorporateGovernance #EquityIncentives #RevenueFocus #GrowthStrategy #HealthcareAI

[Tevogen Bio @TevogenBio]

📢 From Mittul Mehta, Tevogen CIO and Head of @TevogenAI

Reflecting on the past year at https://t.co/VM3narWjpm, I’m proud to share a snapshot of what we’ve built, and where we’re headed.

Through strategic partnerships with @Databricks and @Microsoft, our team has developed a highly curated dataset spanning ~24 million proteins. Using our proprietary data refinement processes, this has expanded into a library of 655 million unique peptides, with nearly 16 billion data points across 12 clinical conditions and the known human genome.

By cross-referencing this work with 37 million expert scientific articles, we’ve been able to enrich our datasets, uncover critical biochemical properties of amino acid chains, identify key anchor residues, and sharpen HLA specificity at scale.

On the modeling front, our PredicTcell™ journey has accelerated rapidly. While the alpha model was trained on ~100,000 data points and served as an important benchmark, the beta version now incorporates 1.8 million data points, representing nearly a 20-fold scale-up.

As we wrap the PredicTcell™ beta and begin training AdapTcell™, I’m excited to continue sharing progress as https://t.co/VM3narWjpm advances toward what many consider the Holy Grail of immunology: Predicting the proteome for any given protein–HLA combination.

More to come.

@drhew @hoifungpoon @TevogenAI @Microsoft @databricks

$TVGN #TevogenAI #AIinBiotech #ComputationalBiology #Immunology #PrecisionMedicine #MachineLearning